# OnCo record paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017" ;
  schema:name "Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)"@en ;
  schema:description "The American head-to-head of the same two antibodies, in 1,137 patients, found no difference: 30.0 against 29.0 months. Read next to FIRE-3, it is why sidedness had to be invoked."@en ;
  schema:url <https://onco.cc/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jama.2017.7105>, <https://pubmed.ncbi.nlm.nih.gov/28632865/>, <https://europepmc.org/article/MED/28632865> ;
  onco:tag "colorectal-evidence" ;
  schema:sameAs <https://doi.org/10.1001/jama.2017.7105> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Venook AP, Niedzwiecki D, Lenz HJ, et al." ;
  onco:related <https://onco.cc/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/>, <https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/> ;
  onco:companies <https://onco.cc/companies/alliance-oncology/>, <https://onco.cc/companies/swog/> ;
  onco:terms <https://onco.cc/terms/sidedness/> ;
  onco:people <https://onco.cc/people/alan-venook/>, <https://onco.cc/people/heinz-josef-lenz/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-negative-results/> ;
  onco:journals <https://onco.cc/journals/jama/> .